Plain-English translation of NCT07180212 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a urine DNA test—a simple, non-invasive test that detects cancer-related changes in your urine—can help doctors decide when you need a cystoscopy (a camera exam of your bladder) for follow-up care. After surgery for high-risk bladder cancer, you normally need regular cystoscopies to check for cancer returning, but these exams can be uncomfortable and sometimes risky. This study hopes to show that combining the urine DNA test with cystoscopy can safely reduce the number of unnecessary camera exams while still catching any cancer that comes back.
High-risk bladder cancer often comes back, so patients need frequent and invasive cystoscopy exams to monitor for recurrence. This trial addresses the problem that these repeated exams are uncomfortable, expensive, and sometimes cause infection or bleeding—so doctors and patients are looking for a simpler, more accurate way to guide follow-up care.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group will have urine DNA and urine tests every 3 months plus one cystoscopy per year (with additional cystoscopies if the urine tests suggest cancer recurrence); the other group will have cystoscopy and urine tests every 3 months as standard care. You may also have additional imaging (a CT scan of your urinary tract) if certain test results warrant it. The study will follow you over time to see whether the urine DNA test approach safely reduces the number of cystoscopies you need while still catching cancer recurrence early.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China